Skip to main content
Top
Published in: Pediatric Drugs 1/2012

01-02-2012 | Adis Profile Report

Candesartan Cilexetil in Children and Adolescents Aged 1 to <17 Years with Hypertension

Profile Report

Authors: Sheridan M. Hoy, Gillian M. Keating

Published in: Pediatric Drugs | Issue 1/2012

Login to get access

Excerpt

In pediatric patients, normal blood pressure (BP) is a function of age, sex, and height percentile; thus, diagnosing hypertension in children and adolescents requires reference to a population distribution.[2] According to the Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents[3] and the European Society of Hypertension guidelines,[4] hypertension in pediatric patients is defined as systolic BP (SBP) and/or diastolic BP (DBP) persistently exceeding the 95th percentile.[3,4] It may manifest secondary to another disease process, such as coarctation of the aorta, endocrine disease, or renal disease, with the likelihood of there being an underlying disease inversely related to age and directly related to the degree of BP elevation.[2,4] Hypertension may also manifest without identifiable cause (essential hypertension).[2] Although, as in adults, essential hypertension is more prevalent than secondary hypertension in pediatric patients, it is rarely observed in infants and young children; the prevalence of essential hypertension is significantly elevated in adolescence and often associated with excess weight and a family history of hypertension or cardiovascular disease.[2,3] …
Literature
1.
go back to reference Hoy SM, Keating GM. Candesartan cilexetil in children and adolescents aged 1 to <17 years with hypertension. Am J Cardiovasc Drugs 2010 Oct; 10(5): 335–42PubMedCrossRef Hoy SM, Keating GM. Candesartan cilexetil in children and adolescents aged 1 to <17 years with hypertension. Am J Cardiovasc Drugs 2010 Oct; 10(5): 335–42PubMedCrossRef
2.
go back to reference Hansen ML, Gunn PW, Kaelber DC. Underdiagnosis of hypertension in children and adolescents. JAMA 2007 Aug; 298(8): 874–9PubMedCrossRef Hansen ML, Gunn PW, Kaelber DC. Underdiagnosis of hypertension in children and adolescents. JAMA 2007 Aug; 298(8): 874–9PubMedCrossRef
3.
go back to reference The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 2004 Aug; 114 (2 Suppl. 4th Report): 555–76 The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 2004 Aug; 114 (2 Suppl. 4th Report): 555–76
4.
go back to reference Lurbe E, Cifkova R, Cruickshank JK, et al. Management of high blood pressure in children and adolescents: recommendations of the European Society of Hypertension. J Hypertens 2009 Sep; 27(9): 1719–42PubMedCrossRef Lurbe E, Cifkova R, Cruickshank JK, et al. Management of high blood pressure in children and adolescents: recommendations of the European Society of Hypertension. J Hypertens 2009 Sep; 27(9): 1719–42PubMedCrossRef
5.
go back to reference Flynn JT. Pediatric hypertension: recent trends and accomplishments, future challenges. Am J Hypertens 2008 Jun; 21(6): 605–12PubMedCrossRef Flynn JT. Pediatric hypertension: recent trends and accomplishments, future challenges. Am J Hypertens 2008 Jun; 21(6): 605–12PubMedCrossRef
7.
go back to reference Schaefer F, Van De Walle J, Zurowska A, et al. Efficacy, safety and pharmacokinetics of candesartan cilexetil in hypertensive children from 1 to less than 6 years of age. J Hypertens 2010 May; 28(5): 1083–90PubMedCrossRef Schaefer F, Van De Walle J, Zurowska A, et al. Efficacy, safety and pharmacokinetics of candesartan cilexetil in hypertensive children from 1 to less than 6 years of age. J Hypertens 2010 May; 28(5): 1083–90PubMedCrossRef
8.
go back to reference Trachtman H, Hainer JW, Sugg J, et al. Efficacy, safety, and pharmacokinetics of candesartan cilexetil in hypertensive children aged 6 to 17 years. J Clin Hypertens 2008 Oct; 10(10): 743–50CrossRef Trachtman H, Hainer JW, Sugg J, et al. Efficacy, safety, and pharmacokinetics of candesartan cilexetil in hypertensive children aged 6 to 17 years. J Clin Hypertens 2008 Oct; 10(10): 743–50CrossRef
Metadata
Title
Candesartan Cilexetil in Children and Adolescents Aged 1 to <17 Years with Hypertension
Profile Report
Authors
Sheridan M. Hoy
Gillian M. Keating
Publication date
01-02-2012
Publisher
Springer International Publishing
Published in
Pediatric Drugs / Issue 1/2012
Print ISSN: 1174-5878
Electronic ISSN: 1179-2019
DOI
https://doi.org/10.2165/11206950-000000000-00000

Other articles of this Issue 1/2012

Pediatric Drugs 1/2012 Go to the issue

Adis Drug Profile

Everolimus